INmune Bio (INMB) shares were 59% lower pre-bell Monday after the company said that a phase 2 trial of its treatment candidate for Alzheimer's disease failed to meet the primary cognitive endpoint in the intent-to-treat population.
Blue Gold (BGL) shares were 24% lower, paring Friday's rally.
Locafy (LCFY) stock was down 17%, shaving gains from the previous session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.